Addition of aliskiren to angiotensin receptor blocker improves ambulatory blood pressure profile and cardiorenal function better than addition of benazepril in chronic kidney disease

International Journal of Molecular Sciences

Volumn 14, Issue 8, 2013, Pages 15361-15375

  Ohsawa, Masato ^a   Tamura, Kouichi ^a   Kanaoka, Tomohiko ^a   Wakui, Hiromichi ^a   Maeda, Akinobu ^a   Dejima, Toru ^a   Azushima, Kengo ^a   Uneda, Kazushi ^a   Kobayashi, Ryu ^a   Tsurumi Ikeya, Yuko ^a   Toya, Yoshiyuki ^a   Fujikawa, Tetsuya ^a   Umemura, Satoshi ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Albuminuria; Ambulatory blood pressure; Direct renin inhibitor; Hypertension (kidney); Left ventricular hypertrophy

Indexed keywords

ALDOSTERONE; ALISKIREN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; PENTOSIDINE; THIAZIDE DIURETIC AGENT;

ADD ON THERAPY; ADULT; AGED; ALBUMINURIA; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; CARDIORENAL FUNCTION; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE MASS; HEART RATE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MALE; MORNING DOSAGE; OPEN STUDY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

AGED; ALBUMINURIA; AMIDES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZAZEPINES; BLOOD PRESSURE; CARDIO-RENAL SYNDROME; FEMALE; FUMARATES; HEART FUNCTION TESTS; HEART RATE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FUNCTION TESTS; MALE; OXIDATIVE STRESS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84880729058     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140815361     Document Type: Article

References (45)

1. Hodgkinson, J.; Mant, J.; Martin, U.; Guo, B.; Hobbs, F.D.; Deeks, J.J.; Heneghan, C.; Roberts, N.; McManus, R.J. Relative effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure monitoring in diagnosis of hypertension: Systematic review. BMJ 2011, 342, d3621.
2. Lovibond, K.; Jowett, S.; Barton, P.; Caulfield, M.; Heneghan, C.; Hobbs, F.D.; Hodgkinson, J.; Mant, J.; Martin, U.; Williams, B. et al. Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: A modelling study. Lancet 2011, 378, 1219-1230.
3. Kikuya, M.; Hozawa, A.; Ohokubo, T.; Tsuji, I.; Michimata, M.; Matsubara, M.; Ota, M.; Nagai, K.; Araki, T.; Satoh, H. et al. Prognostic significance of blood pressure and heart rate variabilities: The Ohasama study. Hypertension 2000, 36, 901-906.
4. Tamura, K.; Kanaoka, T.; Ohsawa, M.; Haku, S.; Azushima, K.; Maeda, A.; Dejima, T.; Wakui, H.; Ozawa, M.; Shigenaga, A. et al. Emerging concept of anti-hypertensive therapy based on ambulatory blood pressure profile in chronic kidney disease. Am. J. Cardiovasc. Dis. 2011, 1, 236-243.
5. Minutolo, R.; Agarwal, R.; Borrelli, S.; Chiodini, P.; Bellizzi, V.; Nappi, F.; Cianciaruso, B.; Zamboli, P.; Conte, G.; Gabbai, F.B. et al. Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease. Arch. Intern. Med. 2011, 171, 1090-1098.
6. Spallone, V.; Bernardi, L.; Ricordi, L.; Solda, P.; Maiello, M.R.; Calciati, A.; Gambardella, S.; Fratino, P.; Menzinger, G. Relationship between the circadian rhythms of blood pressure and sympathovagal balance in diabetic autonomic neuropathy. Diabetes 1993, 42, 1745-1752.
7. Yanagi, M.; Tamura, K.; Fujikawa, T.; Wakui, H.; Kanaoka, T.; Ohsawa, M.; Azushima, K.; Maeda, A.; Kobori, H.; Umemura, S. The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease. Hypertens Res. 2013, 36, 262-269.
8. Nakano, S.; Fukuda, M.; Hotta, F.; Ito, T.; Ishii, T.; Kitazawa, M.; Nishizawa, M.; Kigoshi, T.; Uchida, K. Reversed circadian blood pressure rhythm is associated with occurrences of both fatal and nonfatal vascular events in NIDDM subjects. Diabetes 1998, 47, 1501-1506.
9. Astrup, A.S.; Nielsen, F.S.; Rossing, P.; Ali, S.; Kastrup, J.; Smidt, U.M.; Parving, H.H. Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: A follow-up study. J. Hypertens. 2007, 25, 2479-2485.
10. Palmas, W.; Pickering, T.G.; Teresi, J.; Schwartz, J.E.; Moran, A.; Weinstock, R.S.; Shea, S. Ambulatory blood pressure monitoring and all-cause mortality in elderly people with diabetes mellitus. Hypertension 2009, 53, 120-127.
11. Galle, J. Reduction of proteinuria with angiotensin receptor blockers. Nat. Clin. Pract. Cardiovasc. Med. 2008, 5, S36-S43.
12. Ruggenenti, P.; Remuzzi, G. Proteinuria: Is the ONTARGET renal substudy actually off target? Nat. Rev. Nephrol. 2009, 5, 436-437.
13. Ito, S. Usefulness of RAS inhibition depends on baseline albuminuria. Nat. Rev. Nephrol. 2010, 6, 10-11.
14. Holtkamp, F.A.; de Zeeuw, D.; de Graeff, P.A.; Laverman, G.D.; Berl, T.; Remuzzi, G.; Packham, D.; Lewis, J.B.; Parving, H.H.; Lambers Heerspink, H.J. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: A post hoc analysis of the combined RENAAL and IDNT trials. Eur. Heart J. 2011, 32, 1493-1499.
15. Jensen, C.; Herold, P.; Brunner, H.R. Aliskiren: The first renin inhibitor for clinical treatment. Nat. Rev. Drug Discov. 2008, 7, 399-410.
16. Hollenberg, N.K. Direct renin inhibition and the kidney. Nat. Rev. Nephrol. 2010, 6, 49-55.
17. Parving, H.H.; Brenner, B.M.; McMurray, J.J.; de Zeeuw, D.; Haffner, S.M.; Solomon, S.D.; Chaturvedi, N.; Persson, F.; Desai, A.S.; Nicolaides, M. et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 2012, 367, 2204-2213.
18. Palatini, P.; Jung, W.; Shlyakhto, E.; Botha, J.; Bush, C.; Keefe, D.L. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: Results of a randomized, double-blind study. J. Hum. Hypertens. 2010, 24, 93-103.
19. Kanaoka, T.; Tamura, K.; Ohsawa, M.; Wakui, H.; Maeda, A.; Dejima, T.; Azushima, K.; Haku, S.; Mitsuhashi, H.; Yanagi, M. et al. Effects of aliskiren-based therapy on ambulatory blood pressure profile, central hemodynamics, and arterial stiffness in nondiabetic mild to moderate hypertensive patients. J. Clin. Hypertens. 2012, 14, 522-529.
20. Sander, D.; Kukla, C.; Klingelhofer, J.; Winbeck, K.; Conrad, B. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: A 3-year follow-up study. Circulation 2000, 102, 1536-1541.
21. Eto, M.; Toba, K.; Akishita, M.; Kozaki, K.; Watanabe, T.; Kim, S.; Hashimoto, M.; Ako, J.; Iijima, K.; Sudoh, N. et al. Impact of blood pressure variability on cardiovascular events in elderly patients with hypertension. Hypertens. Res. 2005, 28, 1-7.
22. Pop-Busui, R.; Evans, G.W.; Gerstein, H.C.; Fonseca, V.; Fleg, J.L.; Hoogwerf, B.J.; Genuth, S.; Grimm, R.H.; Corson, M.A.; Prineas, R. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010, 33, 1578-1584.
23. Ozawa, M.; Tamura, K.; Okano, Y.; Matsushita, K.; Yanagi, M.; Tsurumi-Ikeya, Y.; Oshikawa, J.; Hashimoto, T.; Masuda, S.; Wakui, H. et al. Identification of an increased short-term blood pressure variability on ambulatory blood pressure monitoring as a coronary risk factor in diabetic hypertensives. Clin. Exp. Hypertens. 2009, 31, 259-270.
24. Ozawa, M.; Tamura, K.; Okano, Y.; Matsushita, K.; Ikeya, Y.; Masuda, S.; Wakui, H.; Dejima, T.; Shigenaga, A.; Azuma, K. et al. Blood pressure variability as well as blood pressure level is important for left ventricular hypertrophy and brachial-ankle pulse wave velocity in hypertensives. Clin. Exp. Hypertens. 2009, 31, 669-679.
25. Remuzzi, G.; Benigni, A.; Remuzzi, A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J. Clin. Invest. 2006, 116, 288-296.
26. Masuda, S.; Tamura, K.; Wakui, H.; Kanaoka, T.; Ohsawa, M.; Maeda, A.; Dejima, T.; Yanagi, M.; Azuma, K.; Umemura, S. Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy. Hypertens. Res. 2009, 32, 950-955.
27. Bakris, G.L.; Sarafidis, P.A.; Weir, M.R.; Dahlof, B.; Pitt, B.; Jamerson, K.; Velazquez, E.J.; Staikos-Byrne, L.; Kelly, R.Y.; Shi, V. et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): A prespecified secondary analysis of a randomised controlled trial. Lancet 2010, 375, 1173-1181.
28. Parving, H.H.; Persson, F.; Lewis, J.B.; Lewis, E.J.; Hollenberg, N.K. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 2008, 358, 2433-2446.
29. Ito, S.; Nakura, N.; Le Breton, S.; Keefe, D. Efficacy and safety of aliskiren in Japanese hypertensive patients with renal dysfunction. Hypertens. Res. 2010, 33, 62-66.
30. Sakai, Y.; Otsuka, T.; Ohno, D.; Murasawa, T.; Sato, N.; Mizuno, K. Efficacy of aliskiren in Japanese chronic kidney disease patients with hypertension. Ren Fail. 2012, 34, 442-447.
31. Yamamoto, E.; Kataoka, K.; Dong, Y.F.; Nakamura, T.; Fukuda, M.; Tokutomi, Y.; Matsuba, S.; Nako, H.; Nakagata, N.; Kaneko, T. et al. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice. Hypertension 2009, 54, 633-638.
32. Fukuta, H.; Hayano, J.; Ishihara, S.; Sakata, S.; Mukai, S.; Ohte, N.; Ojika, K.; Yagi, K.; Matsumoto, H.; Sohmiya, S. et al. Prognostic value of heart rate variability in patients with end-stage renal disease on chronic haemodialysis. Nephrol. Dial. Transplant. 2003, 18, 318-325.
33. Oikawa, K.; Ishihara, R.; Maeda, T.; Yamaguchi, K.; Koike, A.; Kawaguchi, H.; Tabata, Y.; Murotani, N.; Itoh, H. Prognostic value of heart rate variability in patients with renal failure on hemodialysis. Int. J. Cardiol. 2009, 131, 370-377.
34. Chandra, P.; Sands, R.L.; Gillespie, B.W.; Levin, N.W.; Kotanko, P.; Kiser, M.; Finkelstein, F.; Hinderliter, A.; Pop-Busui, R.; Rajagopalan, S et al. Predictors of heart rate variability and its prognostic significance in chronic kidney disease. Nephrol. Dial. Transplant. Off. Public. Eur. Dial. Transplant. Assoc.-Eur. Renal Assoc. 2012, 27, 700-709.
35. Siddiqi, L.; Prakken, N.H.; Velthuis, B.K.; Cramer, M.J.; Oey, P.L.; Boer, P.; Bots, M.L.; Blankestijn, P.J. Sympathetic activity in chronic kidney disease patients is related to left ventricular mass despite antihypertensive treatment. Nephrol. Dial. Transplant. 2010, 25, 3272-3277.
36. Siddiqi, L.; Oey, P.L.; Blankestijn, P.J. Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients. Nephrol. Dial. Transplant. 2011, 26, 2930-2934.
37. Pouleur, A.C.; Uno, H.; Prescott, M.F.; Desai, A.; Appelbaum, E.; Lukashevich, V.; Smith, B.A.; Dahlof, B.; Solomon, S.D. Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension. J. Renin. Angiotensin. Aldosterone Syst. 2011, 12, 483-490.
38. Mann, J.F.; Schmieder, R.E.; McQueen, M.; Dyal, L.; Schumacher, H.; Pogue, J.; Wang, X.; Maggioni, A.; Budaj, A.; Chaithiraphan, S et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372, 547-553.
39. Fisher, N.D.; Jan Danser, A.H.; Nussberger, J.; Dole, W.P.; Hollenberg, N.K. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008, 117, 3199-3205.
40. Feldman, D.L.; Jin, L.; Xuan, H.; Contrepas, A.; Zhou, Y.; Webb, R.L.; Mueller, D.N.; Feldt, S.; Cumin, F.; Maniara, W. et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008, 52, 130-136.
41. Matsuo, S.; Imai, E.; Horio, M.; Yasuda, Y.; Tomita, K.; Nitta, K.; Yamagata, K.; Tomino, Y.; Yokoyama, H.; Hishida, A. Revised equations for estimated GFR from serum creatinine in Japan. Am. J. Kidney Dis. 2009, 53, 982-992.
42. Pickering, T.G.; Hall, J.E.; Appel, L.J.; Falkner, B.E.; Graves, J.W.; Hill, M.N.; Jones, D.H.; Kurtz, T.; Sheps, S.G.; Roccella, E.J. Recommendations for blood pressure measurement in humans: An AHA scientific statement from the Council on High Blood Pressure Research Professional and Public Education Subcommittee. J. Clin. Hypertens. 2005, 7, 102-109.
43. Mitsuhashi, H.; Tamura, K.; Yamauchi, J.; Ozawa, M.; Yanagi, M.; Dejima, T.; Wakui, H.; Masuda, S.; Azuma, K.; Kanaoka, T. et al. Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis. Atherosclerosis 2009, 207, 186-190.
44. Kanaoka, T.; Tamura, K.; Moriya, T.; Tanaka, K.; Konno, Y.; Kondoh, S.; Toyoda, M.; Umezono, T.; Fujikawa, T.; Ohsawa, M. et al. Effects of Multiple Factorial Intervention on Ambulatory BP Profile and Renal Function in Hypertensive Type 2 Diabetic Patients with Overt Nephropathy-A Pilot Study. Clin. Exp. Hypertens. 2011, 33, 255-263.
45. Kanaoka, T.; Tamura, K.; Ohsawa, M.; Yanagi, M.; Haku, S.; Wakui, H.; Maeda, A.; Dejima, T.; Azushima, K.; Mitsuhashi, H. et al. Relationship of ambulatory blood pressure and the heart rate profile with renal function parameters in hypertensive patients with chronic kidney disease. Clin. Exp. Hypertens. 2012, 34, 264-269.